Table 2.

Summary of clinical and biological studies that investigated the role of CD26 (expressed as soluble form or as surface glycoprotein) in different hematological malignancies.

Reference	Disease	CD26 Presence/Absence	Effect of CD26
[27,28,29]	Follicular/mantle lymphomas	CD26− membrane expression	-
	B-CLL	CD26+ B-cell membrane expression	Disease progression
[30,31,32]	SS	Presence of soluble CD26	Induction of chemiotaxis
		Absence of soluble CD26	Inhibition of chemiotaxis
[33]	T-LGL LPD	CD26+ T cells	Disease progression
		CD26− T cells	Moderate clinical behavior
[34]	MM	CD26+ MM cells	Increase of MM tumor burden
[35,36]	AML	High CD26 plasma levels	Disease progression
[37]	ALL	CD26+ Ph+ p210	Disease progression

Abbreviations: B-CLL, B-Chronic Lymphocytic Leukemia; SS, Sezary syndrome; T-LGL LPD, T-large granular lymphocyte lymphoproliferative disorder; MM, Multiple Myeloma; AML, Acute Myeloid Leukemia; ALL, Acute Lymphoblastic Leukemia; Ph+, Philadelphia Positive; OS, Overall Survival.